Clinical Trial Update: A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) [Phase 3]

View source ↗

Summary

Phase 3 trial of IW-3718 for 8 weeks in GERD patients on PPIs was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• IW-3718

Snippet

Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: TERMINATED | Results posted: 2021-08-18